Besilesomab

Besilesomab
Monoclonal antibody
Type	Whole antibody
Source	Mouse
Target	CEA-related antigen
Clinical data
Trade names	Scintimun
ATC code	none
Identifiers
CAS Number	537694-98-7^N
ChemSpider	none
^NY (what is this?) (verify)

Besilesomab (trade name Scintimun) is a mouse monoclonal antibody labelled with the radioactive isotope technetium-99m. It is used to detect inflammatory lesions and metastases. It binds to an immunoglobulin, IgG1 isotype. SCINTIMUN has been used since 1992 mainly in Hungary, Czech Republic, and Switzerland on the basis of local marketing authorizations, and in Germany (on the basis of individual prescription). Between 1992 and 2009, an estimated 90,000 patients has been studied. In 2009, the EMEA has approved SCINTIMUN for marketing in all European countries.^[1]^[2]

References

↑ WHO Drug Information
↑ Positive opinion of the CHMP for SCINTIMUN (Besilesomab) Archived December 25, 2009, at the Wayback Machine.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Belimumab Brodalumab Carlumab Dupilumab Durvalumab Eldelumab Fresolimumab Golimumab Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oxelumab§ Placulumab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Nivolumab Pembrolizumab Tremelimumab Urelumab Other: Bertilimumab Zanolimumab

Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox

Chimeric ("-lixi-")	Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab

Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab Benralizumab^† Cedelizumab Certolizumab pegol Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Inebilizumab Itolizumab Lampalizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Quilizumab Samalizumab Siplizumab Talizumab Teplizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab^†

Chimeric + humanized ("-lixizu-")	Otelixizumab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab

Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Lebrikizumab Olokizumab Perakizumab Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the 11/14/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.